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Objectives The purpose of this study is to better understand the origins and progression of pre-hypertension.
Background Pre-hypertension is a risk factor for progression to hypertension, cardiovascular disease, and increased mortality.
We used a cross-sectional twin study design to examine the role of heredity in likely pathophysiological events
(autonomic or hemodynamic) in pre-hypertension.
Methods Eight hundred twelve individuals (337 normotensive, 340 pre-hypertensive, 135 hypertensive) were evaluated in a
sample of twin pairs, their siblings, and other family members. They underwent noninvasive hemodynamic, autonomic,
and biochemical testing, as well as estimates of trait heritability (the percentage of trait variance accounted for by heredity)
and pleiotropy (the genetic covariance or shared genetic determination of traits) by variance components.
Results In the hemodynamic realm, an elevation of cardiac contractility prompted increased stroke volume, in turn in-
creasing cardiac output, which elevated blood pressure into the pre-hypertension range. Autonomic monitoring
detected an elevation of norepinephrine secretion plus a decline in cardiac parasympathetic tone. Twin pair vari-
ance components documented substantial heritability as well as joint genetic determination for blood pressure
and the contributory autonomic and hemodynamic traits. Genetic variation at a pathway locus also indicated
pleiotropic effects on contractility and blood pressure.
Conclusions Elevated blood pressure in pre-hypertension results from increased cardiac output, driven by contractility as well
as heart rate, which may reflect both diminished parasympathetic and increased sympathetic tone. In the face
of increased cardiac output, systemic vascular resistance fails to decline homeostatically. Such traits display
substantial heritability and shared genetic determination, although by loci not yet elucidated. These findings clar-
ify the role of heredity in the origin of pre-hypertension and its autonomic and hemodynamic pathogenesis. The
results also establish pathways that suggest new therapeutic targets for pre-hypertension, or approaches to its
prevention. (J Am Coll Cardiol 2012;59:2206–16) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.02.040Pre-hypertension is an emerging and remarkably common
risk factor for not only hypertension, but also cardiovascular
target organ complications. The term pre-hypertension was
efined in 2003 by the Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and
reatment of High Blood Pressure as a systolic blood
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2012, accepted February 14, 2012.pressure (SBP) of 120 to 139 mm Hg, diastolic blood
pressure (DBP) of 80 to 89 mm Hg, or both, although less
than values defined as hypertension (SBP  140 mmHg or
DBP 90 mm Hg) (1). In the United States alone, up to
approximately 41.9 million men and approximately 27.8
million women may exhibit pre-hypertension (2). Pre-
hypertension tends to progress to hypertension over a
relatively short time and is a risk factor for development of
microalbuminuria and cardiovascular disease, with conse-
quently increased mortality (3–7). However, the origins and
pathogenesis of the syndrome are not yet well understood.
Given the serious prognosis for this condition, we under-
took this evaluation of its pathophysiology, with the goals of
not only prevention, but also discovery of novel target processes
for treatment. We therefore used a twin pair design to examine
the role of heredity in the origin of the pre-hypertension trait,
as well as its hemodynamic and autonomic determinants.
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June 12, 2012:2206–16 Pre-Hypertension in TwinsMethods
Demographics. Data were obtained from the University of
California, San Diego, twin/family study population, which
has been described previously (8). Demographics for the
population sample in this study are shown in Table 1. There
were 812 total individuals, comprising 350 monozygotic
twins, 198 dizygotic twins, 233 other siblings of twins, 17
parents of twins, 6 children of twins, and 8 other relatives.
There were 572 females and 240 males. The Human
Research Protection Program at University of California,
Sand Diego, approved the protocol, and each subject gave
informed written consent.
Hemodynamic measurements and blood pressure group
assignments. Data were obtained using a Dynapulse 5200A
oscillometric noninvasive blood pressure monitor (Pulse-
Metric, Vista, California), a device previously validated by
us and others against invasive techniques, including blood
pressure (BP) and cardiac output (CO) (9,10). This monitor
also noninvasively estimated heart rate (HR), mean arterial
pressure, left ventricular (LV) contractility as the change in
pressure divided by change in time (dP/dT), CO, stroke
volume (SV), systemic vascular compliance (SVC), systemic
vascular resistance (SVR), and brachial artery distensibility
(i.e., compliance normalized to size). Cardiac index (CI 
CO/body surface area [BSA]), systemic vascular resistance
index (SVRI  SVR/BSA), and SV index (SV index 
SV/BSA) were calculated using data obtained and BSA.
Measurements were obtained in the seated position after at
least 5 minutes of rest. The cuff was placed on the right arm
with the arm supported at heart level. Measurements for
each subject were obtained in triplicate, and the average of all
3 values were used, if within 10%. Blood pressure values for
each subject were estimated using adjustments to Dynapulse
blood pressure readings using published data (11).
Triplicate-average blood pressures for each individual
were age adjusted (by linear regression) to an age of 40 years.
Normal, pre-hypertensive, and hypertensive blood pressures
were defined by the Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (1). Individuals were
partitioned into the normotensive category if both SBP was
120 mm Hg and DBP was 80 mm Hg; into the
pre-hypertensive category if SBP was 120 to 139 mm Hg,
DBP was 80 to 89 mm Hg, or both; and into the
hypertensive category if either SBP was more than 139 mm Hg or
DBP was more than 89 mm Hg, or both, or they were
taking antihypertensive medications. Forty-four individuals
(5.4%) already were taking antihypertensive drugs and thus
were placed in the hypertension group.
Autonomic function analyses. BIOCHEMISTRY: TRANS-
MITTERS. Plasma catecholamines were measured radioen-
ymatically in 680 individuals: samples were frozen quickly
t 70°C, before a sensitive radioenzymatic assay based on
atechol-O-methylation (12).PHYSIOLOGY: CONTROL OF HR.
BP and HR were recorded contin-
uously and noninvasively for 5
minutes in seated, resting subjects
with a radial artery applanation
device as well as thoracic electro-
cardiogram (ECG) electrodes
and dedicated sensor hardware
(Colin Pilot, Colin Instruments,
San Antonio, Texas) and soft-
ware (ATLAS, W. R. Medical
Electronics, Stillwater, Minne-
sota; and Autonomic Nervous
System, Tonometric Data Analy-
sis [ANS-TDA] System, Colin
Instruments, San Antonio,
Texas). Effects of environmental
stress (cold pressor test: immer-
sion of 1 hand in ice water for 1
minute) on BP and HR were
recorded in triplicate before and
at the end of the stressor. Lorenz
plots and analyses (13) using suc-
cessive beat-to-beat intervals to
evaluate sympathetic (cardiac
sympathetic index; Lorenz L/T
ratio) versus parasympathetic ac-
tivity (cardiac vagal index; Lorenz
log10 [L  T]), were calculated
from 5-minute resting cardiac
monitoring data in seated subjects with ANS-TDA software
in 772 individuals, as described (14).
Genotyping. Genomic DNA was isolated from blood
leukocytes, as has been described previously (15) using
PureGene DNA extraction kits (Gentra Systems, Minne-
apolis, Minnesota). Genotyping was carried out as part of a
single nucleotide polymorphism array (Ilumina 610-Quad,
La Jolla, California) anchored by reference single nucleotide
polymorphism data.
Statistical analyses. Estimates of heritability (h2  VG/VP,
where VG is additive genetic variance and VP is total pheno-
typic variance), as well as shared environmental effects (envi-
ronmental covariance) and pleiotropy (shared genetic determi-
nation or genetic covariance), were obtained from monozygotic
versus dizygotic twin pairs, with variance-component meth-
ods implemented in Sequential Oligogenic Linkage Anal-
ysis Routines (16).
To test the effects of particular genes on traits in the
twin/sibling sample, we used generalized estimating equa-
tions as in SAS software version 9.2 (SAS Institute, Cary,
North Carolina), as previously described (8), in which
correlated (e.g., within twinship) observations can be ac-
counted for by establishing an exchangeable correlation
matrix. To guard against potential artifactual conclusions as
a result of genetic admixture, this analysis was confined to
Abbreviations
and Acronyms
ANOVA  analysis of
variance
BP  blood pressure
BSA  body surface area
CI  cardiac index (cardiac
output/body surface area)
CO  cardiac output
DBP  diastolic blood
pressure
dP/dT  change in
pressure divided by change
in time
dP/dTmax  maximum
change in pressure divided
by change in time
h2  calculated heritability
of a trait
LV  left ventricular
PP  pulse pressure
SBP  systolic blood
pressure
SV  stroke volume
SVR  systemic vascular
resistance
SVRI  systemic vascular
resistance index (SVR 
BSA)individuals self-identified as white.
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Pre-Hypertension in Twins June 12, 2012:2206–16Descriptive statistical analyses among the 3 groups (nor-
motensive, pre-hypertensive, hypertensive) were carried out
using SPSS software version 17.0 (SPSS, Inc., Chicago,
Illinois). Because the participants were twins and therefore
not genetically independent, the effective number of indi-
viduals for any characteristic with substantial heritability
would be less than the actual number of participants, and
the significance (but not the magnitude) of correlations may
be overestimated; a conservative correction would be re-
quirement of a threshold alpha of 0.025 (rather than the
customary 0.05). Overall significance was determined by
generalized linear models using BP group as a fixed factor and
age and sex as covariates. Post-hoc pairwise analyses among the
3 individual groups were carried out with the conservative
Bonferroni correction. All post-hoc p values were Bonferroni-
corrected in SPSS. Spearman (nonparametric rho) and Pear-
son product moment (parametric R) correlations across traits
were calculated in SPSS software as well. Results were plotted
in Kaleidagraph software version 4.02 (Synergy Software,
Reading, Pennsylvania), fitting linear or smoothed curves to
the data, beginning with a Stineman function, whereupon the
output of this function then has a geometric weight applied to
he current point and10% of the data range, to arrive at the
moothed curve. Linear regression also was carried out using
aleidagraph, which calculated the Pearson product mo-
ent correlations with R and p values.
esults
P groups and hemodynamics: heart and vessels.
DEMOGRAPHICS AND BP ITSELF. Characteristics of the
Characteristics of Pre-Hypertensive and Other SubjectsTable 1 Characteristics of Pre-Hypertensive and Other Subjects
Characteristic
B
Normotensive (n  337) Pre-Hypertensive (n
Demographic
Age (yrs) 38.4 0.8 36.3 0.8
Gender (M/F) 51/286 (15.1%/84.9%) 127/213 (37.4%/6
Positive family
history
155 (46%) 185 (54%)
Physical
Weight (kg) 64.9 0.8 76.3 1.0
BMI (kg/m2) 23.65 0.37 26.52 0.36
BSA (m2) 2.11 0.13 2.08 0.13
Biogeographic ancestry
White 237 (70.3%) 211 (62.1%)
Black 13 (3.9%) 44 (12.9%)
Hispanic 32 (9.5%) 34 (10%)
Filipino 1 (0.3%) 9 (2.6%)
East Asian 12 (3.6%) 6 (1.8%)
South Asian 0 2 (0.6%)
Native American 1 (0.3%) 1 (0.3%)
Mixed or other 41 (12.2%) 32 (9.4%)
Values are mean SD, n/N (n %/N %), or n (%). *Not significantly different between pre-hypertensi
3 groups. Bold p values are 0.05.
BMI  body mass index; BSA  body surface area.opulation sample in this study are shown in Table 1, whereas toninvasive hemodynamic results are summarized in Table 2.
verage SBPs for normotensive, pre-hypertensive, and hyper-
ensive individuals were 109.9  0.49 mm Hg, 127.3  0.46
m Hg, and 138.0  0.75 mm Hg, respectively (p  0.001),
hereas DBPs in these groups were 66.3 0.42 mm Hg, 74.4
.41 mm Hg, and 78.9  0.67 mm Hg, respectively (p 
.001). Mean SBP and DBP in the hypertensive group were
lightly lower than Seventh Report of the Joint National
ommittee on Prevention, Detection, Evaluation, and
reatment of High Blood Pressure definitions for hyper-
ension because of the inclusion of 44 individuals taking
ntihypertensive medications. Mean arterial pressure (p 
.001) and pulse pressure (PP) (p  0.001) also rose across
he BP categories. HR also differed (p  0.001), rising
ystematically with BP.
Biogeographic ancestries differed across the BP groups,
ith an increased frequency of pre-hypertension among
frican Americans (p  0.001), consistent with different
opulation prevalence of hypertension by ancestry. Age was
ot different between normotensive and pre-hypertensive
ubjects, although it was substantially higher in the hyper-
ensive subjects (p  0.001), consistent with the age-
ependent penetrance of the hypertension trait. Men were
ore likely than women to exhibit pre-hypertension (p 
.001), also consistent with known hypertension demo-
raphics. Weight rose by approximately 15 kg across the
roups (p  0.001), and body mass index also rose by
pproximately 3 kg/m2 (p  0.001), whereas overall body
ize (as BSA) did not change (p  0.155).
HEMODYNAMIC DETERMINANTS OF BP. Hemodynamic de-
ressure Group
p Value0) Hypertensive (n  135) Total (N  812)
45.3 1.7 38.6 0.6 <0.001
62/73 (45.9%/54.1%) 240/572 (29.6%/70.4%) <0.001
80 (58%) 420 (52%) 0.001
82.0 1.7 72.5 0.6 <0.001
26.99 0.59 25.41 0.24 <0.001
2.53 0.21 2.16 0.08 0.155
77 (55.2%) 525 (64%) <0.001†
20 (14.6%) 77 (9.5%)
20 (14.6%) 86 (10.6%)
0 10 (1.2%)
3 (2.2%) 21 (2.6%)
0 2(0.2%)
0 2 (0.2%)
15 (10.9%) 89 (10.9%)
hypertensives. †p value derived from chi-square to detect differences across all ethnicities amonglood P
 34
2.6%)
ves anderminants of BP were strikingly different across the 3
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June 12, 2012:2206–16 Pre-Hypertension in Twinsgroups (Table 2). CO (p 0.001), CI (p 0.001), SV (p
0.001), and SV index (p  0.001) also were different by
analysis of variance (ANOVA) across the 3 groups; these
traits also differed between the normotensive and pre-
hypertensive categories, although not significantly between
pre-hypertensives and hypertensives on post hoc analysis (al-
though values for these categories tended to increase as BP
increased). Systemic vascular compliance (p  0.001) and
brachial artery distensibility (p  0.001) tended to decrease as
BP increased; the overall changes were significantly different by
ANOVA, although principally between normotensive and
pre-hypertensive groups, rather than pre-hypertensives and hy-
pertensives on post hoc analysis. SVR and SVRI were not
significantly different among the 3 groups.
Within the heart, the maximum LV dP/dT (dP/dTmax; a
measure of cardiac contractility) significantly (p  0.001)
increased across the normotensive, pre-hypertensive, and
hypertensive groups, with values of 1097.4  8.89 mm Hg/s,
263.8  8.87 mm Hg/s, and 1347.6  14.6 mm Hg/s,
espectively. The increase in LV dP/dTmax correlated highly
with SBP across the groups (R2 0.528) (Figs. 1A and 1B),
uggesting that up to approximately 53% of variation in SBP
ould be accounted for by the distribution of dP/dT.
PULSE PRESSURE. PP (PP  SBP  DBP) also increased
cross the 3 groups (Table 2, Fig. 1C), from 56.2  0.49
m Hg, 61.8  0.48 mmHg, and 68.0  0.79 mm Hg,
espectively (p 0.001). Among likely contributors across the
P groups, LV contractility increased (p  0.001), whereas
ystemic vascular compliance decreased as BP increased, with
alues of 1.31 0.013 ml/mm Hg, 1.25 0.013 ml/mm Hg,
nd 1.21  0.022 ml/mm Hg (p  0.001).
Autonomic function: biochemical and physiological.
Results are summarized in Table 3. Plasma norepinephrine
Hemodynamic Determinants of Pre-Hypertension, Compared With NTable 2 Hemodynamic Determinants of Pre-Hypertension, Com
Trait
Blood Pressure Group
Normotensive Pre-Hypertensive Hype
SBP (mm Hg) 109.9 0.49 127.3 0.46 138.
DBP (mm Hg) 66.3 0.42 74.4 0.41 78.
MAP (mm Hg) 83.4 0.42 94.6 0.41 100.
Pulse pressure (mm Hg) 52.6 0.49 61.8 0.48 68.
Heart rate (beats/min) 67.8 0.62 70.7 0.61 72.
LV dP/dTmax (mm Hg/s) 1,097.4 8.89 1,263.8 8.74 1,347.
Cardiac output (l/min) 4.60 0.70 5.33 0.69 5.6
Cardiac index (l/min/m2) 2.66 0.031 2.84 0.03 3.0
Stroke volume (ml) 67.6 0.716 74.5 0.70 75.
Stroke volume index (ml/m2) 38.9 0.26 40.5 0.26 40.
SVC (ml/mm Hg) 1.31 0.013 1.25 0.013 1.2
SVR (dynes·s/cm5) 1,502.9 17.7 1,499.5 17.48 1,505.
SVR index (dynes·s/cm5/m2) 3,171.3 229.5 3,135.0 223.34 3,971.
BA distensibility (%/mm Hg) 7.45 0.072 6.37 0.071 6.2
Values are mean  SD. Bold p values are 0.05.
BA  brachial artery; DBP  diastolic blood pressure; dP/dTmax  maximum change in pressu
pressure; SVC  stroke volume compliance; SVR  systemic vascular resistance.levels increased with BP (p  0.028), although onlyormotensive and hypertensive groups differed on post hoc
nalysis (Figs. 2A and 2B); plasma epinephrine did not
iffer across the groups. Lorenz beat-to-beat values probed
ardiac sympathetic versus parasympathetic activity (13).
orenz log10 (L  T), a measure of parasympathetic
ctivity, differed overall (p  0.050), with the principal
ubgroup difference being between normotensives and hy-
ertensives (p 0.046). The scatterplot (Fig. 2C) illustrates
he contribution of cardiac parasympathetic activity to basal
eart rate. The Lorenz L/T ratio, a measure of sympathetic
ctivity, did not differ among the 3 groups. During envi-
onmental (cold) stress, changes in SBP, DBP, or HR did
ot differ among the 3 groups (in contrast to longitudinal
eports [17]).
enetic analyses. TRAIT HERITABILITY. Trait heritability
(h2) values are summarized in Table 4 and are illustrated in
Figure 3A. Using variance components from twin data, we
estimated trait h2 values at: SBP, 44.6  6.7% (p  0.001);
lasma norepinephrine, 65.2  5.0% (p  0.001); HR, 62.2 
.3% (p  0.001); Lorenz log10 [L  T] (parasympathetic)
index, 22.2 8.0% (p 0.004); LV dP/dTmax 35.3 7.4%
(p  0.001); CI, 60.5  5.6% (p  0.001); and SVR, 57.3 
5.6% (p  0.001).
GENETIC AND ENVIRONMENTAL COVARIANCES. LV dP/
T, SVR, CI, HR, and plasma epinephrine and norepi-
ephrine levels were examined for shared genetic deter-
ination with SBP, DBP, or both in the twin pairs
Table 4, Fig. 3B). Of these, only LV dP/dT and CI
howed any significant genetic covariance overlap with
BP (CI: p  0.001, LV dP/dT: p  0.001). None of
these traits showed heritable association with DBP. Also,
SVR, CI, and LV dP/dT displayed environmental cova-
riance with SBP (SVR: p  0.005, CI: p  0.007, LV
tensive and Hypertensive SubjectsWith Normotensive and Hypertensive Subjects
p Value
ve Overall
Normotensive vs.
Pre-Hypertensive
Normotensive vs.
Hypertensive
Pre-Hypertensive
vs. Hypertensive
75 <0.001 <0.001 <0.001 <0.001
67 <0.001 <0.001 <0.001 <0.001
68 <0.001 <0.001 <0.001 <0.001
79 <0.001 <0.001 <0.001 <0.001
00 <0.001 <0.001 <0.001 0.279
.6 <0.001 <0.001 <0.001 <0.001
115 <0.001 <0.001 <0.001 0.126
050 <0.001 <0.001 <0.001 0.123
18 <0.001 <0.001 <0.001 1.000
43 <0.001 <0.001 0.001 1.000
022 0.001 0.015 0.002 0.436
.18 0.982 1.000 1.000 1.000
4.8 0.135 1.000 0.221 0.165
118 <0.001 <0.001 <0.001 1.000
ed by change in time; LV  left ventricular; MAP  mean arterial pressure; SBP  systolic bloodormopared
rtensi
0 0.
9 0.
7 0.
0 0.
7 1.
6 14
1 0.
2 0.
5 1.
7 0.
1 0.
4 29
7 37
7 0.dP/dT: p  0.001) (Fig. 3B).
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PLEIOTROPY. We further explored pleiotropic genetic ef-
ects on SBP with its more proximal determinants: either CI
r LV dP/dT. Because the L-type voltage operated calcium
Figure 1 Pre-Hypertension: Role of the Heart and Left Ventricle
(A) Systolic blood pressure (SBP) and diastolic blood pressure (DBP) as a func
pressure divided by change in time [dP/dTmax]) in normotensive, pre-hypertens
as a function of LV contractility, as measured by LV dP/dTmax. Linear regressio
namic determinants. Average pulse pressure in normotensive, pre-hypertensive
sided y-axis) and brachial artery distensibility (dashed line, left-sided y-axis). In
the decrease in arterial distensibility.hannel controls not only vascular smooth muscle tone,
ut also cardiac contractility and sympathetic transmitter
elease, we began with the characteristic alpha-subunit of
oltage operated calcium channel that confers L-type
tractility
f left ventricular (LV) contractility (as measured by LV change in maximum
d hypertensive groups. (B) Scatterplot of all 813 individuals, with SBP shown
hown as well. (C) Pulse pressure (PP) elevation in pre-hypertension: hemody-
hypertensive groups versus LV contractility as LV dP/dTmax (solid line, right-
s in PP are the result of a combination of the increase in LV contractility andCon
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June 12, 2012:2206–16 Pre-Hypertension in Twinsspecificity: alpha-1C (CACNA1C) (18), which displayed
several single nucleotide polymorphisms associated with
both LV dP/dTmax and SBP. To illustrate the asso-
ciation, we focus on the CACNA1C intron-3 variant
rs2239050 allele, because it has been associated previ-
ously with both BP and dihydropyridine response (18).
CACNA1C genetic variation (Fig. 3C) predicted both LV
dP/dT (p  0.008) and SBP (p  0.001), and multivar-
iate ANOVA also indicated a pleiotropic or coordinate effect
of the gene on both traits (p 0.001). At this G/C variant, our
population sample displayed 91% G/9% C alleles, in Hardy
Weinberg equilibrium (p  0.681), and consistent with Eu-
ropean populations reported in the HapMap (19). Given the
minor allele frequency of 9%, the number of minor allele
homozygotes (C/C) was small (n  4), and hence we com-
bined C/C and G/C individuals, in effect testing a C-allele
dominant model for each trait.
Discussion
Overview: novel findings. Our results suggest that in-
creases in BP in pre-hypertension result from a pathway
initiated by heritable disturbances displaying joint genetic
determination, and then actuated by autonomic and hemo-
dynamic events in series (Fig. 4).
Role of heredity. The twin sample provided us with an
unusual opportunity to probe for early heritable origins of
pre-hypertension. Heritability (h2) is the fraction of trait
ariance attributable to genetic variation (20). The h2 values
document substantial genetic determination of not only
SBP and DBP, but also several associated pathogenic traits:
CI, plasma norepinephrine levels, cardiac parasympathetic
index (Lorenz log10 [L  T]), SVR, and cardiac contrac-
tility measured by LV dP/dTmax. Genetic covariance (or
pleiotropy) analyses indicate that these correlated traits
share heritable determination (i.e., coordinate gene action
on more than 1 trait). The findings thus illustrate that
Autonomic Function in Pre-HypertensionTable 3 Autonomic Function in Pre-Hypertension
Trait
Blood Pressure Group
Normotensive Pre-hypertensive Hyper
Cold pressor test
Delta (change in) SBP 13.6 1.23 12.9 1.21 12.9
Delta (change in) DBP 11.1 0.73 10.3 0.72 11.5
Delta (change in) HR 3.4 0.64 4.8 0.62 4.2
Lorenz beat-to-beat
HR variability
Lorenz log L  T
(parasympathetic)
0.945 0.360 0.979 0.035 1.114
Lorenz L/T (sympathetic) 2.125 0.072 2.147 0.070 2.132
Plasma catecholamines
Epinephrine (pg/ml) 28.7 1.41 28.7 1.39 32.4
Norepinephrine (pg/ml) 320.5 9.55 343.8 9.43 368.7
Values are mean  SD. Bold p values are 0.05.
HR  heart rate; L  longitudinal axis; T  transverse axis; abbreviations as in Table 2.genetic predisposition to pre-hypertension (and hence hy- spertension) is initiated through pleiotropic gene effects,
initially on pathogenic autonomic traits (e.g., parasympa-
thetic and sympathetic tone), and later on hemodynamic
traits (e.g., cardiac contractility or LV dP/dTmax). Not all
raits associated or correlated with SBP and DBP in our
ample displayed genetic covariance; indeed, some (SVR,
V dP/dTmax, CI) evinced shared environmental determi-
nation, in the form of environmental covariance. Thus,
genes alone are not adequate to explain risk for development
of pre-hypertension or hypertension itself; indeed, gene-by-
environment interactions also may be at work (21).
The full spectrum of genetic variation underlying hyperten-
sion is only now beginning to emerge and remains incompletely
understood (22–25). Allelic variation at CACNA1C has been
associated with BP response to calcium channel blockers
(18,26), or even BP itself (27). Association of CACNA1C
ariant rs2239050 predicted both cardiac contractility and SBP
Fig. 3C), and the multivariate ANOVA confirmed a pleio-
ropic effect of the locus on both traits. Variant rs2239050 lies
ithin an intron, and thus is unlikely to be the causal variant;
owever, systematic polymorphism discovery at CACNA1C
28) revealed 46 polymorphisms across the approximately
00-kbp locus, including several potentially functional variants.
utonomic function: sympathetic and parasympathetic.
here was an overall increase in plasma norepinephrine levels
s BP and HR increased; the increment in norepinephrine is a
ovel finding in pre-hypertension, whereas epinephrine was
nchanged. Several previous reports suggest catecholamine
ncrements in hypertension (29–33). Age and obesity also can
ffect catecholamine levels, even independent of BP (29,34).
he increased norepinephrine could account in part for the
ncrease we saw in contractility. Increased norepinephrine
ecretion also may contribute to unchanged SVR, which
therwise would be expected to decrease reflexively in the face
f elevated CO (35).
cross the BP groups, HR rose progressively. To under-
p Value
e Overall
Normotensive vs.
Pre-Hypertensive
Normotensive vs.
Hypertensive
Pre-Hypertensive
vs. Hypertensive
4 0.928 1.000 1.000 1.000
2 0.637 1.000 1.000 1.000
5 0.33 0.411 1.000 1.000
58 0.05 1.000 0.046 0.140
16 0.977 1.000 1.000 1.000
2 0.359 1.000 0.568 0.531
.81 0.028 0.262 0.031 0.531tensiv
 2.0
 1.2
 1.0
 0.0
 0.1
 2.3
 15tand why, we used Lorenz plots to generate selective
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Pre-Hypertension in Twins June 12, 2012:2206–16physiological indices of cardiac sympathetic versus parasym-
pathetic activity. Parasympathetic activity (as Lorenz log10
[L  T]) was decreased in hypertension, with intermediate
Figure 2 Pre-Hypertension: Role of the Autonomic Nervous Sys
(A) Sympathetic system and blood pressure (BP). Average plasma norepinephrine
sive groups, with a line of best fit. (B) Sympathetic system and LV contractility. Av
hypertensive, and hypertensive groups. (C) Parasympathetic system and heart rat
Lorenz log10 (L  T). Note that heart rate decreases as the parasympathetic index
nation). Abbreviations as in Figure 1.values in pre-hypertension, consistent with the increase in
HR seen in our data and other studies, rather than an
increase in cardiac sympathetic activity (36,37); indeed,
versus average SBP and DBP in normotensive, pre-hypertensive, and hyperten-
plasma norepinephrine levels versus average LV dP/dTmax in normotensive, pre-
tterplot of basal heart rate versus cardiac parasympathetic index, measured as
ases. Linear regression line is also shown, and R2 value (coefficient of determi-tem
levels
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2213JACC Vol. 59, No. 24, 2012 Davis et al.
June 12, 2012:2206–16 Pre-Hypertension in Twinsdecline in parasympathetic tone seemed to account for up to
approximately 11% of HR variance (R2  0.111) (Fig. 2C).
n increase in HR during pre-hypertension has been
eported in white persons and American Indians, although
ot in African Americans (36).
emodynamics: heart and vessels. Because BP is the
lgebraic product of CO (or CI  CO/BSA) and SVR
SVRI  SVR/BSA; i.e., mean arterial pressure  CO 
VR), we evaluated these traits in pre-hypertension and
ound that increased CO, rather than SVR, accounted for
P elevation in pre-hypertension. In turn, given that CO 
VHR, the elevation of CO in pre-hypertension resulted
rom increments of both SV and HR. The increment in SV
as driven by elevated cardiac contractility (LV dP/dTmax).
Finally, the elevated HR was attributed primarily to a
decline in parasympathetic tone, as evidenced by the cardiac
vagal index, although norepinephrine results also pointed to
an elevation in sympathetic activity.
The norepinephrine increment also suggested that an
increase in sympathetic activity contributed to (or perhaps
even accounted for) the rise in LV dP/dT (Table 3, Fig. 2B).
An overall schema integrating our results into a likely
pathogenic sequence of events for pre-hypertension is given
in Figure 4.
PP (PP  SBP  DBP) is an emerging independent risk
factor for cardiovascular morbidity (7), and widening of PP in
the past has been attributed to either increased cardiac con-
tractility or diminished vascular compliance (38). Our data
indicate that PP already is increased in pre-hypertension and
that the change can be attributed to both elevated contractility
and diminished vascular compliance, even at this early stage.
Our observation of an increase in cardiac contractility, as
measured by LV dP/dTmax, with a failure of SVR to decrease
ppropriately. Although this has been seen in hypertensive
atients previously (39), our data are unique in that they shows
hat there may be a progressive increase in cardiac contractility
ith BP. Similar data in pre-hypertension have been reported
n the past for CO: an increase in CO in pre-hypertensives may
ccur without significant change in SVR (36,37,40). However,
easures of contractility have not been obtained previously:
ur data show a striking correlation with increasing LV
P/dTmax and increasing SBP. Other factors involved in CO,
uch as SV and HR, seem to become altered at the pre-
ypertension phase, but do not change further as individuals
rogress to hypertension.
We did not detect differences in SVR (or SVRI) across the
groups. It should be noted that the expected homeostatic
esponse to an increase in cardiac contractility and CO would
e a decline in SVR to restore BP to normal. Thus, a failure of
VR decline can contribute pathogenically to elevated BP.
The emerging cardiovascular risk factor PP (PP  SBP 
BP) (7) already was elevated (by approximately 17.5%),
ven in pre-hypertension. Why did this occur? We noted 2
lausible mechanisms: both elevated cardiac contractilityand decreased arterial distensibility.He
T P H L L C S
Va
lu A
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Pre-Hypertension in Twins June 12, 2012:2206–16Figure 3 Pre-Hypertension: Role of Heredity
(A) Heritability (h2) of traits contributing to BP elevation: results from twin pair variance components. (B) Graphical representation of shared genetic (i.e., pleio-
tropic) versus shared environmental effects on SBP. The other heritable traits are: systemic vascular resistance (SVR), cardiac index (CI), and LV dP/dTmax. Above
the diagonal line of identity (Y  X) lies primarily codetermination by environmental covariance (rE), whereas below the line lies primarily genetic covariance (rG).
Each covariance is presented as mean  SEM for the estimate. (C) SBP as a function of contractility (LV dP/dTmax) when stratified by CACNA1C rs2239050
genotype. Groups are composed of those with the G/G genotype (major allele homozygotes) versus those with either the C/G or C/C genotypes. CVI  cardiac
vagal index; GEE  generalized estimating equation; HWE  Hardy Weinberg equilibrium; other abbreviations as in Figures 1 and 2.
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2215JACC Vol. 59, No. 24, 2012 Davis et al.
June 12, 2012:2206–16 Pre-Hypertension in TwinsStudy advantages and limitations. First, the twin study
design allowed us to probe the role of heredity in both
hypertension and its genetically codetermined precursor events.
Our study also is comprehensive in that it couples multiple
hemodynamic and autonomic indices across BP strata.
Limitations in the study include its cross-sectional (rather
than longitudinal) design. Finally, although we focused on
autonomic and hemodynamic determinants of BP in this
report, our pre-hypertensives demonstrated a body mass
index increment of approximately 2.9 kg/m2 over their
ormotensive counterparts; in other reports, an early eleva-
ion of body mass index in pre-hypertension, with its
ssociated metabolic traits, also may be central to the
yndrome (41).
onclusions
ur findings indicate that the onset of pre-hypertension
ay be genetically determined at least in part and the result
f joint heritability among a cluster of BP-correlated auto-
omic and hemodynamic traits. In the autonomic realm, an
ncrement in sympathetic tone, coupled with a decline in
arasympathetic tone, may be pathogenic. Within hemo-
ynamic determinants of BP, an elevation in cardiac
ontractility (augmenting SV) seems to drive an increase
n CO, accounting for elevated BP, perhaps assisted by
ack of homeostatic decline in SVR. The increment in PP
eems to result from pathogenic changes in both LV
ontractility and arterial distensibility. The role of genetic
Figure 4 Pathophysiology of Pre-Hypertension
Proposed hypothetical schema representing the pathophysiology of pre-hypertensio
ceptibility to hypertension eventually demonstrate autonomic and biochemical trait
with a failure of SVR to decrease appropriately, eventually manifest themselves asleiotropy in trait determination is reinforced by theoordinate effects of genetic variation at a single locus on
oth contractility and BP.
Thus far, deliberate treatment approaches to pre-
ypertension have been focused mainly on angiotensin receptor
lockade (42,43) or nonpharmacological means (44), such as
ietary modification (DASH [Dietary Approaches to Stop
ypertension] diet) (45) or weight reduction. Our results
ocument several additional points for logical and rational
herapeutic intervention in pre-hypertension, including ele-
ated sympathetic outflow (suggesting alpha-2-adrenergic ag-
nist treatment), increased cardiac contractility (suggesting
eta-adrenergic antagonist treatment), decreased arterial dis-
ensibility, and participation of CACNA1C (Fig. 3C) (suggest-
ng L-type voltage operated calcium channel antagonists).
onetheless, because adrenergic pathways subserve many
unctions in addition to BP, antiadrenergic drugs may exhibit
ore frequent central nervous system side effects than newer
rugs targeting the angiotensin system (46). A recent meta-
nalysis indicates that a variety of cardiovascular agents used
uring secondary prevention trials even in subjects without
ypertension may be effective in diminishing risk of subsequent
ascular events, although investigators agree that more data on
ndividual drugs would be useful (43).
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hypertension, based on data in this report. Individuals with genes causing sus-
, over time, cause physiologic changes. These changes, such as increased CI
ased SBP and DBP. Abbreviations as in Figures 1 and 3.n and
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